Conformational landscape of platinum(II)-tetraamine complexes: DFT and NBO studies

The potential energy surfaces of chiral tetraamine Pt(II) coordination complexes were computed at the B3LYP/LANL2DZ level of theory by a systematic variation of two dihedral angles: C12–C15–C34–C37 (θ) and C24–C17–C31–C48 (ψ) employing a grid resolution of 30°. Potential energy surfaces calculated using density functional theory methods and Boltzmann-derived populations revealed strong preference for one diasteromer of each series studied. In addition, natural bond orbital analysis show that the minima are stabilized predominantly by a combination of electronic interactions between two phenyl groups, the phenyl groups and the Pt2+ ion, as well as with the amine groups. Additional experimental characterization of the diasteroisomers studied here is in progress and will permit further molecular modeling studies with the appropriate stereochemistry.

[1]  R A Houghten,et al.  Mixture-based synthetic combinatorial libraries. , 1999, Journal of medicinal chemistry.

[2]  Shuzhong Zhang,et al.  Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.

[3]  W. R. Wadt,et al.  Ab initio effective core potentials for molecular calculations. Potentials for K to Au including the outermost core orbitals , 1985 .

[4]  Li-June Ming,et al.  Metal binding and structure-activity relationship of the metalloantibiotic peptide bacitracin. , 2002, Journal of inorganic biochemistry.

[5]  Eric Meggers,et al.  Exploring biologically relevant chemical space with metal complexes. , 2007, Current opinion in chemical biology.

[6]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[7]  Kevin B. Nolan,et al.  The preparation and crystal and molecular structure of the complex cis-PtCl2(razoxane) , 1998 .

[8]  Tatsuyuki Kanamori,et al.  Dimeric Macrocyclic Polyamines with Potent Inhibitory Activity against Human Immunodeficiency Virus , 1995 .

[9]  Eric Meggers,et al.  Platinum complex as a nanomolar protein kinase inhibitor. , 2007, Inorganic chemistry.

[10]  María Teresa Garland,et al.  Structural and coordinating properties of platinum(II) chloride complexes with polypyridyl ligands. Single crystal X-ray structure of [Pt(ddpq)Cl2]·H2O (ddpq=6,7-dimethyl-2,3-di(2-pyridyl)quinoxaline) , 2001 .

[11]  P. Charifson,et al.  Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand reorganization upon binding. , 2004, Journal of medicinal chemistry.

[12]  Katherine S. Lovejoy,et al.  cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects , 2008, Proceedings of the National Academy of Sciences.

[13]  Keith T. Butler,et al.  Toward accurate relative energy predictions of the bioactive conformation of drugs , 2009, J. Comput. Chem..

[14]  Thomas Ludwig,et al.  Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. , 2004, Kidney international.

[15]  David J. Yang,et al.  Diammine Dicarboxylic Acid Platinum Enhances Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells through Induction of Apoptosis and S-Phase Cell Arrest , 2008, Pharmaceutical Research.

[16]  Mercedes Camalli,et al.  Structural features of a new dinuclear platinum(II) complex with significant antiproliferative activity. , 2003, Inorganic chemistry.

[17]  A. Bansal,et al.  Antiandrogen and Antimicrobial Aspects of Coordination Compounds of Palladium(II), Platinum(II) and Lead(II) , 2001, Metal-based drugs.

[18]  Archimede Rotondo.  (6,7-Dimethyl-2,3-di-2-pyridylquinoxaline)bis(3-methylpyridine)platinum(II) bis(hexafluorophosphate) acetone solvate 0.5-hydrate. , 2006, Acta crystallographica. Section C, Crystal structure communications.

[19]  W. R. Wadt,et al.  Ab initio effective core potentials for molecular calculations. Potentials for main group elements Na to Bi , 1985 .

[20]  W. R. Wadt,et al.  Ab initio effective core potentials for molecular calculations , 1984 .

[21]  A. Raya,et al.  Ab initio quantum mechanical characterization of platinum, palladium, and nickel complexes of L‐ascorbic acid , 2002 .

[22]  Dik-Lung Ma,et al.  Some uses of transition metal complexes as anti-cancer and anti-HIV agents. , 2007, Dalton transactions.

[23]  Barnett Rosenberg,et al.  Charles F. Kettring prize. Fundamental studies with cisplatin , 1985 .

[24]  Clemencia Pinilla,et al.  Synthesis of platinum(II) chiral tetraamine coordination complexes. , 2006, Journal of combinatorial chemistry.

[25]  Robert J Woods,et al.  On achieving experimental accuracy from molecular dynamics simulations of flexible molecules: aqueous glycerol. , 2008, The journal of physical chemistry. A.

[26]  Clemencia Pinilla,et al.  Advances in the use of synthetic combinatorial chemistry: Mixture-based libraries , 2003, Nature Medicine.

[27]  Eric Meggers,et al.  Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. , 2006, Journal of the American Chemical Society.

[28]  Eric Meggers,et al.  Targeting proteins with metal complexes. , 2009, Chemical communications.

[29]  J M Bidlack,et al.  An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. , 1994, Science.

[30]  M. Abrams,et al.  Medicinal inorganic chemistry: introduction. , 1999, Chemical reviews.

[31]  Peter Mayer,et al.  Synthesis, cytotoxic effect, and structure-activity relationship of Pd(II) complexes with coumarin derivatives. , 2006, Inorganic chemistry.

[32]  L S Hollis,et al.  Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+. , 1989, Journal of medicinal chemistry.

[33]  B. Hasinoff,et al.  Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). , 2004, Journal of inorganic biochemistry.

[34]  M. Christian,et al.  New Cisplatin Analogues in Development , 1993, Drugs.

[35]  L. Steven Hollis,et al.  Synthesis, structure and antitumor properties of platinum complexes of vitamin C , 1985 .